Literature DB >> 6309731

The elimination of sulbactam alone and combined with ampicillin in patients with renal dysfunction.

N Wright, R Wise.   

Abstract

Sulbactam, a beta-lactamase inhibitor, was given as a single agent to 12 subjects with varying degrees of renal dysfunction. The half-life in normal subjects was 1.1 h and increased to 21.3 h in those with terminal renal failure. Sulbactam together with ampicillin was given to a further five subjects. It was concluded that if the two agents are given together, the plasma ratio of one to the other will remain constant whatever the renal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309731     DOI: 10.1093/jac/11.6.583

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.

Authors:  R A Blum; R K Kohli; N J Harrison; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  New sensitive bioassay for sulbactam in bovine tissues.

Authors:  G H Keeler; J P Stankewich; A E Girard; J J Rash
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 5.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

8.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.